Jafron Biomedical Co

Jafron Biomedical Co EBIT Margin

The EBIT Margin (Operating Margin) of Jafron Biomedical Co (300529.SZ) as of Nov 14, 2026 is 36.76 %. In the previous year, EBIT Margin (Operating Margin) was 39.05 % — a change of -5.86% (lower).

EBIT Margin

36.76 %

YoY

-5.86%

Last updated:

EBIT Margin (Operating Margin) of Jafron Biomedical Co is 2025 36.76 % . EBIT Margin (Operating Margin) of Jafron Biomedical Co was 2024 39.05 % . It decreases by -5.86% lower compared to the previous year.

Jafron Biomedical Co's operating (EBIT) margin stands at 36.8%, down from 53.0% several years earlier.

The Jafron Biomedical Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
46.86 CNY
Jan 1, 2019
47.52 CNY
Jan 1, 2020
54.05 CNY
Jan 1, 2021
53.00 CNY
Jan 1, 2022
41.32 CNY
Jan 1, 2023
28.29 CNY
Jan 1, 2024
39.05 CNY
Jan 1, 2025
36.76 CNY
The Jafron Biomedical Co EBIT Margin history
YEAREBIT MarginYoY
36.76 %-5.86%
39.05 %+38.02%
28.29 %-31.54%
41.32 %-22.03%
53.00 %-1.94%
54.05 %+13.75%
47.52 %+1.40%
46.86 %+1.49%
46.17 %+7.87%
42.80 %-6.14%
45.60 %-2.82%
46.92 %+10,062.76%
0.46 %+6.94%
0.43 %-2.39%
0.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

EBIT Margin (Operating Margin) of Jafron Biomedical Co is 36.76 % in 2025.

EBIT Margin (Operating Margin) of Jafron Biomedical Co changed from 39.05 % to 36.76 %, representing a -5.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Jafron Biomedical Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Jafron Biomedical Co